Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2025-08-20 Report Publication Anno…
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
关于延期披露公司2025年半年度报告的公告
Report Publication Announcement Classification · 100% confidence The document is an announcement from Yunnan Watson Biotechnology Co., Ltd. regarding the delay in the disclosure of its 2025 semi-annual report. It states the original disclosure date and the new postponed date, explains the reason for the delay, and reassures investors about the company's operational status. The document is short (752 characters) and does not contain any actual financial data or the report itself. It is clearly an announcement about the timing of a report, not the report itself. According to the 'MENU VS MEAL' rule, this type of document should be classified as a Report Publication Announcement (RPA).
2025-08-20 Chinese
关于呼吸道合胞病毒mRNA疫苗临床研究申请获得受理的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company regarding the acceptance of a clinical trial application for a new mRNA vaccine by the national drug regulatory authority. It contains no financial data, no financial results, no management discussion, no meeting materials, no voting results, no share transactions, no legal proceedings, and no regulatory certifications. It is a regulatory announcement about a clinical trial application acceptance, which fits best under general regulatory announcements that do not fit other categories. The document length is short (994 characters), and it is an announcement rather than a report or detailed filing. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2025-08-03 Chinese
第五届董事会第三十次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board of directors meeting of Yunnan Watson Biotechnology Co., Ltd. It details the meeting date, attendance, and specific decisions made, including approval of an amendment to a sublicense agreement and approval of credit facilities from various banks. The document includes voting results and references to related announcements on a regulatory disclosure website. There are no financial statements or detailed financial data presented, nor is this a report or presentation. The content focuses on board decisions and approvals, which fits the category of Board/Management Information (MANG). The document length is about 2054 characters, which is typical for a meeting resolution announcement rather than a full report. Therefore, the appropriate classification is MANG with high confidence.
2025-07-30 Chinese
关于签署微生态健康靶向技术独家再许可协议之修正案的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by a company about the signing of an amendment to an exclusive sublicense agreement. It details the terms of the amendment, the parties involved, financial arrangements, and the impact and risks related to the agreement. There are no financial statements, quarterly or annual results, or detailed financial performance data. The document is a formal announcement of a contractual agreement and its amendment, not a financial report or earnings release. It also includes board meeting resolutions related to the agreement but does not announce changes in board or management personnel. Therefore, the document fits best into the category of a general regulatory announcement about a material contract or business update, which corresponds to Regulatory Filings (RNS). The document length is about 5,000 characters, and it is not merely a brief notice or a report publication announcement. Hence, the classification is RNS with high confidence.
2025-07-30 Chinese
第五届监事会第二十一次会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement of a supervisory board meeting resolution regarding the company's and its subsidiaries' application for credit facilities from various banks. It details the meeting date, participants, agenda, and voting results. The content focuses on approval of financing arrangements (credit lines) for operational needs. There are no financial statements, earnings data, or detailed financial analysis present. The document is not a full financial report but an update on capital/financing activities. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is short and it is not merely announcing the publication of a report but providing substantive information about financing decisions.
2025-07-30 Chinese
关于公司及子公司向银行申请授信额度的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's and its subsidiaries' application for credit facilities from various banks. It details the proposed credit amounts, terms, and purposes, and includes approvals from the board of directors and supervisory board. There are no financial statements or detailed financial performance data presented. The document is a formal disclosure of financing activities, specifically about credit/loan applications, which fits the category of Capital/Financing Update (CAP). The document length is short (2152 characters), and it is not merely announcing the publication of a report but providing substantive information about financing plans. Therefore, the appropriate classification is CAP with high confidence.
2025-07-30 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.